Douglas HoughDavid KuoEsther T ChanMatthew C LaFavePetrus Rudolf de JongDavid G BelairBrion W MurrayBrittany TaylorDanielle GregorSeungkyu LeeAndrew J SchwartzJake GockleyChristopher C ParkG E RingheimWarren L DenningKen OgasawaraKai WangAndrea GrayKevin H ChenIrina MedvedevaPrajwal ThoolSamuel A Danziger
P108
A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the PancreasAn Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)A Study to Determine Dose and Tolerability of CC-220 Monotherapy, in Combination With Dexamethasone, and in Combination With Dexamethasone and Daratumumab or Bortezomib in Subjects With Relapsed and Refractory Multiple Myeloma (MM)A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaAn Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 MutationOpen-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative ColitisEfficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's DiseaseSafety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative ColitisPhase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 MutationEvaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple MyelomaDrug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3AStudy to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISEA Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus ErythematosusABI-009 Trial in Patients With Advanced Non-hematologic MalignanciesFirst Line Therapy for Patients With Metastatic Breast CancerPhase II Study With CC-10004 in Psoriatic ArthritisEfficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple MyelomaA Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell LymphomaA Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaA Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaA Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic LeukemiaA Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's DiseaseStudy of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior TherapyMulti-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus ErythematosusA Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on HemodialysisACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaLenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid ArthritisNab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet DiseaseA Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant MelanomaEfficacy and Safety Study of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)Non-Interventional Study in Patients With Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) to Investigate the Association of Lenalidomide With Tumor Flare Reaction and High Tumor BurdenDrug-drug Interaction Study of Ozanimod With Pseudoephedrine to Evaluate the Effect on Blood Pressure and Heart RateAn Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis
P859
Q43125301-144CE9A1-9B0E-4E98-B153-42739A38BFA0Q43644283-6183A34F-78B7-4B83-86D4-0BEAB0C3EB11Q47503077-7A013FEA-0FA7-48A7-8805-369A28CA8785Q56911384-2AEE3D9B-A01B-4AD0-9AFA-EAD87F86B599Q57053538-201A1CD1-F93A-46F6-8B40-A202DD7B75D0Q57149318-FCD83F19-0483-4BCE-9DFA-42A1B1AB0433Q57178561-1793A739-47A7-4D74-BA8A-3F5D8CE18CF2Q57431305-3D298EA6-F1CE-435B-ADE9-5C1FFE2DA7ABQ57910843-B5AC0684-BFC1-4E4B-9F28-24B09D50253CQ60912425-3D351DA9-43C1-4475-94CA-741811F1B5E9Q61698779-31111CCC-CC0A-4BC2-BE56-AA7BC9165FB3Q63937974-821E8CE5-6841-47E7-AB76-C4BEEA1488F8Q64356079-6952716D-9F89-437C-B9E8-E7F11B0E9CD4Q70871466-9D3212AB-2295-4F24-86CE-5F4179D49FBCQ79287405-47DD1636-7945-4704-9ADC-2BF843CCFE3EQ79807723-2F53495A-1ED4-4080-A719-01474AB0C428Q80092935-7E9DF265-6D28-41C7-A637-0859818A04EDQ87278024-E0D287FB-47FE-4DC8-9BE2-B40C6E0A9BDCQ88067848-BF6AF84D-EC62-4FA1-8260-680F1EDDA156Q88595217-256D6FFB-37C3-4B92-ABDC-38EEDAF8BF12Q89674539-26B6BACC-48A3-4ADC-BA76-7DFD8AC69567Q89723292-3C54B545-9F25-4B2C-93CB-63F1F39BEC93
P108
Q47477264-65509806-4429-34b3-583a-2b7f0a18868bQ61862174-E1264B01-8E57-48E5-8F2F-23CE040E9CB0Q61862177-7931E07E-4AEB-4F08-8ED6-9F2A884A3600Q61862214-43C64533-5F8F-4215-AEF8-7E4F7C9DBBF3Q61862227-75C8A2DA-2140-49CD-B667-184E0B14E9CBQ61862232-ED38B400-F6CF-4EFB-A626-54BA8E81BEE8Q61862245-37CD9010-246A-4648-B679-3D26A322C528Q61862246-F08949E3-CC57-4276-ACF9-48451A5B3C99Q61862270-F97E4915-5D1D-41E2-A37B-0C5FEAB9AB1EQ61864805-5AB771D0-0823-484C-84DA-021CF0667279Q61864809-86AA5399-CD67-4EBE-AAB3-2342B2D790F2Q61864842-3FAEC03F-2578-43F7-BDB1-1C82875B29A9Q61902236-9E21CC98-BD2B-4D9C-99DB-1BB11F8CD8E6Q61907024-313D75D1-8053-4F3C-B0FC-F1F58965A724Q61909194-6F731300-E868-405B-8EAB-0EFDC9FB12A9Q61915425-830F4EED-BBC2-43CE-B8D6-8C4D8AD7C6CCQ61920517-370659B1-9442-4223-BFC4-28DD6C32EF67Q61920577-46FDD90A-3ECD-4CCE-8BE0-7024E0549500Q61920864-8081A088-4EFC-41F0-AA6D-70AAC825FC0FQ61921409-745AC76D-D19E-4D28-8858-67048822AA01Q61921635-44484174-02B0-4D7A-B96D-06AB3033FCD9Q61921933-DC51B811-50B8-49F6-AE63-41F96F7C4B72Q61922099-4B540BD7-DD2A-40D4-9AE9-6E897DF5910CQ61924430-80F795EA-376E-439E-B5F9-22302570FB34Q61932385-922A6AC6-90F0-4AD6-9DAE-821816EF785EQ61936231-68DB08A3-381C-4D1C-B9DA-37A4E320154DQ61938394-E53FF760-8140-4211-AACB-38462BE82AE5Q61956281-544DF234-E352-45AE-8BE3-900B1A03F731Q61966088-6D44C26B-500C-4A04-90E3-DDBE93AED00DQ61969359-9075F87A-950F-48F7-8CFA-509FF36EB165Q61969493-3471A415-CA5D-4769-8125-5C1131B7C924Q61969570-BEA531DA-22AB-4AB8-8FA5-6F5B1DBBA4ECQ61974944-34F66E80-AE0F-4166-A1FB-56DCEE9859E2Q61975843-746E243E-D8C8-4912-8D37-8B939EA591FAQ61980995-3881C08E-119B-4EF1-9DA0-6705A83A0A34Q61981180-29DC7868-C2A5-4691-902A-D2AE757A38BBQ62025368-6994D419-E8D4-45F6-9DD8-E118E652B7D6Q62025694-104213CC-385E-48D6-9E0F-835FB7F0048EQ62025893-591CF757-A6B0-4BD1-931B-B0353117B775Q62030742-DF03A3F2-B569-4149-A991-EC78D7EE0C25
P859
description
American biopharmaceutical company
@en
US-amerikanisches Unternehmen
@de
americká firma
@cs
bedrijf uit Verenigde Staten van Amerika
@nl
enterprise
@fr
name
Celgene
@da
Celgene
@de
Celgene
@en
Celgene
@et
Celgene
@fi
Celgene
@fo
Celgene
@fr
Celgene
@is
Celgene
@it
Celgene
@kl
type
label
Celgene
@da
Celgene
@de
Celgene
@en
Celgene
@et
Celgene
@fi
Celgene
@fo
Celgene
@fr
Celgene
@is
Celgene
@it
Celgene
@kl
altLabel
Celgene Corporation
@de
Celgene Corporation
@en
prefLabel
Celgene
@da
Celgene
@de
Celgene
@en
Celgene
@et
Celgene
@fi
Celgene
@fo
Celgene
@fr
Celgene
@is
Celgene
@it
Celgene
@kl
P31
P3153
P646
P1056
P1454
P159
P2003
P2427
grid.418722.a
P2657
37955905654-37
P3153
P3225
4010001106378
P3393
39756-Celgene_Corporation
P414
P571
1986-01-01T00:00:00Z
P646
P946
US1510201049